Taking into account the epidemiological situation of COVID-19 and following the Recommendations of the Interterritorial Council of the National Health System, the Community of Madrid will carry out a vaccination campaign against flu and COVID-19 in the autumn-winter season of 2023-2024, started on October 16.
Joint vaccination (flu and COVID-19) is recommended for population groups that have a higher risk of complications or serious conditions if they suffer from the infection, as well as health and social care personnel, and essential public services personnel.
Population groups with indication for vaccination:
- People aged 60 and over.
- People aged 5 or over in nursing homes and disability centers, as well as other people institutionalized for a long time and residing in closed institutions.
- People under 60 years of age with risk conditions.
- Pregnant women in any trimester of pregnancy and women during the postpartum period (up to 6 months after giving birth and who have not been vaccinated during pregnancy).
- People living with those who have a high degree of immunosuppression: in general it refers to transplanted hematopoietic progenitors, solid organ transplants, chronic renal failure, HIV infection with low CD4 count (<200 cells/ml), some primary immunodeficiencies) and those undergoing certain immunosuppressive therapies. Cohabitants of people with other higher risk and older diseases may also be included.
- Staff of public and private health and social health centers and establishments (except students).
- People who work in essential public services, with special emphasis on the following groups:
- State security forces and bodies, with national, regional or local dependence.
- Civil protection services.
In this campaign, following the indications of the European Center for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA), monovalent vaccines against COVID-19 adapted to the XBB strain will be used.
People who are contraindicated for mRNA vaccines against COVID-19 may receive the protein vaccines availables.
will be administered single dose of vaccine regardless of the number of doses received previously, at least 3 months since the last dose administered or since the last SARS CoV2 infection.
People with severe immunosuppression may also require an additional dose, separated by at least 3 months.
In the pediatric population aged 6-59 months with risk conditions, without a history of vaccination against COVID-19 or previous infection, a three-dose schedule at 0-3-8 weeks is recommended.
Vaccination will be prioritized in nursing homes and other disability care centers and the population aged 80 and over.